title: The introduction of verteporfin photodynamic therapy in the UK: PDT users group (PDTUG) surveillance programme report 1.
abstract: OBJECTIVE
  To report overall patient recruitment characteristics and visual acuity (VA) outcome related to baseline lesion characteristics for patients with choroidal neovascularisation (CNV) treated with verteporfin photodynamic therapy (PDT) during its introduction into routine National Health Service practice.
  
  
  METHODS
  Thirteen treatment centres prospectively submitted data on patients undergoing verteporfin PDT for CNV of mixed aetiology between November 1999 and May 2004 into the PDT Users Group (PDTUG) surveillance database. The primary outcome was the proportion of eyes losing <15 letters of VA at 12 and 24 months, follow-up compared with the baseline examination.
  
  
  RESULTS
  One thousand eight hundred and ninety-four eyes of 1755 patients were analysed. Lesion characteristics at baseline were: classic no occult 1152 (67.4%), predominantly classic with occult 531 (31.1%). Recruitment rate rose steadily from 13 in the first to 188 in the final quarter. Data were available at 12 months on 1010 (53.3%) and at 24 months on 310 (16.4%) eyes. The proportion of eyes losing <15 letters was 71% (716/1010) at 12 months and 70% (217/310) at 24 months. At 12 months 91% (917/1010) of patients lost <30 letters. The mean number of PDT treatments for the cohort was 2.4 in the first 12 months. An adverse reaction or event was reported in 8.1% (364/4515) of treatments. Non-visual adverse events were infrequent.
  
  
  CONCLUSIONS
  Efficacy and safety of verteporfin PDT in reducing vision loss in macular degeneration can be reproduced in routine clinical practice. Compared to the TAP study, the fewer treatments needed in the PDTUG cohort indicate the potential for better cost-effectiveness.
authors.affiliation: Department of Ophthalmology, Bradford Teaching Hospitals NHS Foundation Trust, Royal Infirmary, Bradford, UK. faruque.ghanchi@bradfordhospitals.nhas.uk
authors.forename: F D
authors.initials: FD
authors.lastname: Ghanchi
authors.forename: J
authors.initials: J
authors.lastname: Fullarton
authors.forename: J
authors.initials: J
authors.lastname: Blake
authors.forename: S P
authors.initials: SP
authors.lastname: Harding
mesh_terms: D000368:Aged; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D006113:United Kingdom; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin